Major adverse cardiovascular event ( MACE ) occurred in 7.9 % vs. 8.2 % , MI in 2.4 % vs. 3.0 % , TLR in 5.5 % vs. 3.0 % , and stent thrombosis in 0 vs. 1.5 % ; and events were comparable between the HELIOS group and PARTNER group at three-year follow-up ( all P > 0.05 ) .